Glucotrack (GCTK) Net Equity Issued and Repurchased (2011 - 2020)

Glucotrack (GCTK) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $13.0 million in Q1 2020.

• Quarterly Net Equity Issued and Repurchased rose 1634.27% year-over-year to $13.0 million in Q1 2020, while the trailing twelve-month figure through Dec 2020 was $13.0 million (up 202.22% YoY) and the FY2020 annual result came in at $13.0 million, up 212.34% from the prior year.
• Net Equity Issued and Repurchased grew to $13.0 million in Q1 2020, from -$79.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $13.0 million in Q1 2020 to a low of -$79.0 in Q4 2019.
• A 4-year average of $3.0 million and a median of $924398.0 in 2018 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2019 — Net Equity Issued and Repurchased slumped 100.06% — and 2020, when it soared 1634.27%.
• Tracing GCTK's Net Equity Issued and Repurchased over 4 years: stood at $7.3 million in 2016, then tumbled by 98.09% to $139416.0 in 2018, then tumbled by 100.06% to -$79.0 in 2019, then surged by 16467188.61% to $13.0 million in 2020.
• The last three Net Equity Issued and Repurchased figures came in at $13.0 million (Q1 2020), -$79.0 (Q4 2019), and $3.4 million (Q2 2019), per Business Quant data.